Fair Value Measurements (Details) (USD $) In Thousands, unless otherwise specified	9 Months Ended			3 Months Ended		9 Months Ended		12 Months Ended	9 Months Ended	12 Months Ended	9 Months Ended	12 Months Ended	9 Months Ended	12 Months Ended	9 Months Ended	12 Months Ended	9 Months Ended	12 Months Ended	6 Months Ended	9 Months Ended	12 Months Ended	9 Months Ended	12 Months Ended	9 Months Ended	12 Months Ended	9 Months Ended	12 Months Ended	9 Months Ended	12 Months Ended	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2013	Sep. 30, 2014 Auction Rate Securities [Member]	Sep. 30, 2013 Auction Rate Securities [Member]	Sep. 30, 2014 Auction Rate Securities [Member]	Sep. 30, 2013 Auction Rate Securities [Member]	Dec. 31, 2013 Auction Rate Securities [Member]	Sep. 30, 2014 Auction Rate Securities [Member] Minimum [Member]	Dec. 31, 2013 Auction Rate Securities [Member] Minimum [Member]	Sep. 30, 2014 Auction Rate Securities [Member] Maximum [Member]	Dec. 31, 2013 Auction Rate Securities [Member] Maximum [Member]	Sep. 30, 2014 Auction Rate Securities [Member] Weighted average [Member]	Dec. 31, 2013 Auction Rate Securities [Member] Weighted average [Member]	Sep. 30, 2014 Azedra commercialization [Member]	Dec. 31, 2013 Azedra commercialization [Member]	Sep. 30, 2014 MIP - 1404 commercialization [Member]	Dec. 31, 2013 MIP - 1404 commercialization [Member]	Jun. 30, 2014 MIP-1095 commercialization [Member]	Sep. 30, 2014 MIP-1095 commercialization [Member]	Dec. 31, 2013 MIP-1095 commercialization [Member]	Sep. 30, 2014 Net sales targets [Member]	Dec. 31, 2013 Net sales targets [Member]	Sep. 30, 2014 Net sales targets [Member] Minimum [Member]	Dec. 31, 2013 Net sales targets [Member] Minimum [Member]	Sep. 30, 2014 Net sales targets [Member] Maximum [Member]	Dec. 31, 2013 Net sales targets [Member] Maximum [Member]	Sep. 30, 2014 Net sales targets [Member] Weighted average [Member]	Dec. 31, 2013 Net sales targets [Member] Weighted average [Member]	Sep. 30, 2014 Contingent Consideration Liability [Member]	Sep. 30, 2013 Contingent Consideration Liability [Member]	Sep. 30, 2014 Contingent Consideration Liability [Member]	Sep. 30, 2013 Contingent Consideration Liability [Member]	Sep. 30, 2014 U.S. Government Subsidized Securities [Member]	Sep. 30, 2014 Recurring [Member]	Dec. 31, 2013 Recurring [Member]	Sep. 30, 2014 Recurring [Member] Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]	Dec. 31, 2013 Recurring [Member] Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]	Sep. 30, 2014 Recurring [Member] Significant Other Observable Inputs (Level 2) [Member]	Dec. 31, 2013 Recurring [Member] Significant Other Observable Inputs (Level 2) [Member]	Sep. 30, 2014 Recurring [Member] Significant Unobservable Inputs (Level 3) [Member]	Dec. 31, 2013 Recurring [Member] Significant Unobservable Inputs (Level 3) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration liability	$ 17,100	$ 15,700	$ 15,900																																$ 17,100	$ 15,700	$ 0	$ 0	$ 0	$ 0	$ 17,100	$ 15,700
Money Market Funds																																			70,397	60,364	70,397	60,364	0	0	0	0
Auction Rate Securities	2,208	2,208																																2,208	2,208	2,208	0	0	0	0	2,208	2,208
Asset, total																																			72,605	62,572	70,397	60,364	0	0	2,208	2,208
Liability, total																																			17,100	15,700	0	0	0	0	17,100	15,700
Maturity period of US government subsidized securities (in years)	10 years
Duration of securities subject to temporary impairment, minimum (in months)	12 months
Amount of temporary impairment	192	192
Summary of activities in financial instruments with significant Level 3 inputs [Roll Forward]
Balance at beginning of period				2,208	2,208	2,208	3,240	3,240																						16,600	15,900	15,700	0
Transfers into Level 3				0	0	0	0
Total realized/unrealized gains (losses)
Included in net income (loss)				0	0	0	0
Included in other comprehensive incomet (loss)				0	0	0	68
Settlements				0	0	0	(1,100)
Fair value of contingent consideration - acquisition of Molecular Insight																																0	15,900
Fair value change to contingent consideration included in net loss																														500	0	1,400	0
Balance at end of period				2,208	2,208	2,208	2,208	2,208																						17,100	15,900	17,100	15,900
Changes in unrealized gains or losses for the period included in earnings (or changes in net assets) for liabilities held at the end of the reporting period																														500	0	1,400	0
Total amount of unrealized gains (losses) for the period included in other comprehensive loss attributable to the change in fair market value of related assets still held at the reporting date				0	0	0	0
Fair Value Measurements, Quantitative Information
Period of milestone expected achievement															2017	2017	2018	2018		2021	2021			2018	2018	2022	2022
Fair Value				$ 2,208		$ 2,208		$ 2,208							$ 2,400	$ 2,300	$ 2,200	$ 2,000		$ 500	$ 500	$ 12,000	$ 10,900
Valuation technique						Discounted cash flow model		Discounted cash flow model							Probability adjusted discounted cash flow model	Probability adjusted discounted cash flow model	Probability adjusted discounted cash flow model	Probability adjusted discounted cash flow model		Probability adjusted discounted cash flow model	Probability adjusted discounted cash flow model	Monte-Carlo simulation	Monte-Carlo simulation
Redemption period									5 years	5 years	15 years	15 years	6 years	6 years
Discount Rate									0.25%	0.25%	3.00%	3.00%	1.55%	1.55%	10.00%	10.00%	10.00%	10.00%	10.00%		10.00%	12.50%	12.50%
Probability of success															40.00%	40.00%	31.00%	31.00%		19.00%	19.00%			19.00%	19.00%	40.00%	40.00%	32.80%	32.80%